Logo
x

Search category

Subscribe Now

Astellas

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

  • August 18, 2023
Astellas Reports the US FDA’s Acceptance of sNDA for Cresemba (isavuconazonium sulfate) to Treat Fungal Infections

Astellas Reports the US FDA’s Acceptance of sNDA for Cresemba (isavuconazonium sulfate) to Treat Fungal Infections

  • August 11, 2023
Astellas Entered into a Research Collaboration and License Agreement with PeptiDream to Discover Novel Targeted Protein Degraders

Astellas Entered into a Research Collaboration and License Agreement with PeptiDream to Discover Novel Targeted Protein Degraders

  • July 27, 2023
Astellas Entered into a License Agreement with 4D Molecular Therapeutics for Rare Ophthalmic Targets Using 4DMT's Intravitreal R100 Vector

Astellas Entered into a License Agreement with 4D Molecular Therapeutics for Rare Ophthalmic Targets Using 4DMT's Intravitreal R10...

  • July 12, 2023
Astellas Signed a Research Collaboration and Exclusive Option Agreement with Cullgen to Advance Innovative Targeted Protein Degraders

Astellas Signed a Research Collaboration and Exclusive Option Agreement with Cullgen to Advance Innovative Targeted Protein Degrad...

  • June 15, 2023
PharmaShots Weekly Snapshots (June 05 – 09, 2023)

PharmaShots Weekly Snapshots (June 05 – 09, 2023)

  • June 10, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.